- Letter to the Editor
- Open Access
The Swedish Medical Products Agency’s rules of procedure
© The Author(s). 2018
- Received: 29 June 2018
- Accepted: 18 September 2018
- Published: 15 November 2018
The Commentary to this article has been published in Health Research Policy and Systems 2018 16:108
The Letter to the Editor to this article has been published in Health Research Policy and Systems 2018 16:98
The Swedish Medical Products Agency (MPA) is the Swedish national authority responsible for regulation and surveillance of the development, manufacturing and marketing of medicinal products. Relenza, a neuraminidase inhibitor used in the treatment of influenza, has been evaluated by both the Swedish MPA and the United States Food and Drug Administration.
In a paper by Mulinari et al. , the divergent conclusions reached by the authorities are discussed. The purpose of this letter is not to discuss the conclusions drawn by Mulinari et al. , but to comment on the way they refer to an assessor at the MPA. By naming a specific assessor at the MPA, the reader is given the false impression that a single employee is solely responsible for the benefit–risk evaluation of a drug. We want to emphasize that all assessments at the MPA are the work of a team of assessors with complementary competencies, including a comprehensive standardized quality assessment procedure for each decision. Hence, it is the MPA, as a national regulatory agency, that is responsible for any opinion or decision. Besides giving a misleading description of regulatory procedures, the publication of an individual assessor’s name adds no scientific value to the paper and could therefore have been omitted.
CAF wrote the manuscript. The author read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The author declares that she has no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Mulinari S, Davis C. Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews. Health Res Policy Syst. 2017;15:93. https://doi.org/10.1186/s12961-017-0259-8.View ArticlePubMedPubMed CentralGoogle Scholar